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Abstract
Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytoma predominantly affecting 
children and young adults. We performed comprehensive genomic characterization on 
a cohort of 67 patients with histologically defined PXA (n  =  53, 79%) or anaplastic 
PXA (A-PXA, n  =  14, 21%), including copy number analysis (ThermoFisher Oncos-
can, n  =  67), methylation profiling (Illumina EPIC array, n  =  43) and targeted next 
generation sequencing (n  =  32). The most frequent alterations were CDKN2A/B dele-
tion (n = 63; 94%) and BRAF p.V600E (n = 51, 76.1%). In 7 BRAF p.V600 wild-type 
cases, alternative driver alterations were identified involving BRAF, RAF1 and NF1. 
Downstream phosphorylation of ERK kinase was uniformly present. Additional patho-
genic alterations were rare, with TERT, ATRX and TP53 mutations identified in a 
small number of tumors, predominantly A-PXA. Methylation-based classification of 
46 cases utilizing a comprehensive reference tumor allowed assignment to the PXA 
methylation class in 40 cases. A minority grouped with the methylation classes of 
ganglioglioma or pilocytic astrocytoma (n = 2), anaplastic pilocytic astrocytoma (n = 2) 
or control tissues (n  =  2). In 9 cases, tissue was available from matched primary and 
recurrent tumors, including 8 with anaplastic transformation. At recurrence, two tumors 
acquired TERT promoter mutations and the majority demonstrated additional non-
recurrent copy number alterations. Methylation class was preserved at recurrence. For 
62 patients (92.5%), clinical follow-up data were available (median follow-up, 5.4 years). 
Overall survival was significantly different between PXA and A-PXA (5-year OS 80.8% 
vs. 47.6%; P = 0.0009) but not progression-free survival (5-year PFS 59.9% vs. 39.8%; 
P  =  0.05). WHO grade remained a strong predictor of overall survival when limited 
to 38 cases defined as PXA by methylation-based classification. Our data confirm the 
importance of WHO grading in histologically and epigenetically defined PXA. Meth-
ylation-based classification may be helpful in cases with ambiguous morphology, but 
is largely confirmatory in PXA with well-defined morphology.
INTRODUCTION
Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytic 
neoplasm predominantly affecting children and young adults. 
PXA is defined histologically by the presence of large pleo-
morphic, spindled and lipidized cells, numerous eosinophilic 
granular bodies and dense pericellular reticulin (13). PXA 
has a relatively favorable prognosis, but a higher tendency 
to recur than other pediatric low-grade gliomas, leading to 
its designation as a WHO grade II neoplasm. Up to one 
third of PXA show features of anaplasia, characterized by 
increased mitotic activity and at times necrosis, which is 
associated with decreased overall survival (16). As such, 
anaplastic PXA (A-PXA) is designated WHO grade III in 
the 2016 WHO Classification of Central Nervous System 
Tumors (12).
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PXAs are characterized by genetic alterations of the 
mitogen-activated protein kinase (MAPK) pathway. The 
majority harbor BRAF p.V600E mutation, which has been 
identified in 60-78% of tumors (13). Other MAPK altera-
tions have been identified in a smaller fraction of PXA, 
including BRAF insertion/deletion mutations (29), fusions 
involving BRAF or RAF1 (15, 28) and mutation of NF1 
(4). The majority of PXA also harbor homozygous deletion 
of CKDN2A/B. Initial studies identified this alteration in 
approximately 60% of cases (39) while more recent reports 
have found a higher incidence (>85%) (27, 36). PXAs show 
frequent additional copy number changes, most commonly 
whole chromosome or whole chromosomal arm gains and 
losses. Recurrent alterations reported across multiple studies 
include loss −9 or −9p, and loss −22; recurrent gains include 
+7, +5, +20 and +21 (27, 36, 39). The genetic alterations 
underlying recurrence and anaplasia are not well understood. 
A recent study of 19 PXA patients, including 15 A-PXA, 
identified TERT promoter alterations in 47% of A-PXA. 
Mutations of ATRX, PTEN, TP53 and BCOR/BCORL1 
were also identified in single cases of A-PXA (27). 
Additionally, genomic analyses have been performed on a 
small number of matched primary and recurrent tumors 
undergoing anaplastic transformation. These studies identi-
fied complex changes in chromosomal copy number as well 
as acquisition of mutations in TERT, ARID1A and NF1 
upon recurrence and anaplastic transformation (27, 36).
PXA can present a diagnostic challenge as it shares over-
lapping genomic features with multiple other tumor types. 
BRAF p.V600E is a common alteration in many low-grade 
glial and glioneuronal tumors (31). Concurrent MAPK 
alterations and CDKN2A/B deletion is also frequent in epi-
thelioid glioblastoma (1, 19, 20, 24), pediatric secondary 
high-grade gliomas (25) and the recently described anaplastic 
astrocytoma with piloid features (30). Additionally, as 
genome-wide methylation-based classification is increasingly 
utilized in the diagnosis of brain tumors (6), multiple stud-
ies have identified tumors with a “PXA-like” methylation 
profile, including epithelioid glioblastoma (15), astroblastoma 
(23) and a subset of pediatric gliomas (24). The precise 
relationship of these tumors to PXA and their long-term 
prognosis remains uncertain. Methylation-based classification 
is not able to differentiate between PXA and A-PXA (6).
To more fully understand the genomics of PXA, its long-
term prognosis and its relationship to other MAPK-altered 
tumors, we performed a comprehensive genomic analysis of 
a cohort of 67 patients with histologically defined PXA and 
correlated the findings with long-term clinical follow-up. Our 
results confirm that the majority of PXA are characterized 
by CDKN2A/B deletion and MAPK activation and that WHO 
grading remains an important prognostic factor in PXA.
MATERIALS AND METHODS
Patient cohort
We identified 67 patients who underwent resection of a 
PXA or A-PXA with pathology reviewed Mayo Clinic 
(n = 30), Johns Hopkins Hospital (JHH) (n = 5) or University 
of Bonn (n  =  32).
All studies were conducted in accordance with the ethical 
standards of the Declaration of Helsinki. Studies were 
approved by the Institutional Review Boards of Mayo Clinic 
and JHH. The use of clinical data and biologic material 
is in conformity with the ethics regulation standards of the 
University of Bonn Medical Center. Cases reviewed at 
University of Bonn included patients in German pediatric 
low-and high-grade glioma trials. All tumors underwent 
histologic review with confirmation of diagnosis by at least 
two neuropathologists (C.G, T.P, F.R. and R.V.). A-PXA 
was defined by the presence of 5 or more mitotic figures 
per 10 high-power fields (field size of 0.23 mm2) consistent 
with 2016 WHO criteria (12). A subset of 29 patients from 
the Mayo Clinic/JHH cohort was included in previous clini-
cal (16) and genomic studies (36). One patient had an 
apparent clinical diagnosis and family history of neurofi-
bromatosis (case 63) without other manifestations or known 
germline testing. One patient (case 22) harbored a germline 
deletion of CKDN2A/B and presented with multiple, bilateral 
PXAs.
Immunohistochemistry
Immunohistochemistry was performed on FFPE sections 
using antibodies directed against p16INK4a (mouse mono-
clonal anti-p16, clone E6H4, Roche Diagnostics, Mannheim, 
Germany) and BRAF V600E (mouse monoclonal anti-
BRAF V600E, clone VE1, Roche Diagnostics, Mannheim, 
Germany) using a Ventana Benchmark XT Immunostainer 
(Roche Ventana, Darmstadt, Germany). Immunohisto-
chemistry for phospho-ERK was studied as described 
before (32); a detailed method is provided in the sup-
plementary methods.
Genome-wide chromosomal copy number 
analysis
DNA was extracted from 5-micron formalin-fixed paraffin 
embedded (FFPE) tissue sections using the QIAamp DNA 
FFPE Tissue Kit (Qiagen, Hilden, Germany) as described 
(17). Genomic copy number losses and gains were identi-
fied with a molecular inversion probe array (MIP) 
(OncoScan CNV Plus Array, Thermo-Fisher Scientific, 
Waltham, MA, USA). The array covers frequent copy 
number changes across 900 cancer genes. Using at least 
80  ng tumor DNA, MIP was performed as previously 
described (38). Briefly, all probes contain two genomic 
homology regions each flanking a SNP site. Gaps were 
filled and ligated after annealing to the DNA, followed 
by digestion of  remaining non-circularized probes by exo-
nucleases. After cleavage the now inverted probes were 
amplified by PCR using universal primers, followed by 
labeling with fluorescent molecules and hybridization to 
oligonucleotide chip arrays. Raw data were analyzed using 
the Nexus Copy Number 8.0 Discovery Edition software 
(BioDiscovery, El Segundo, CA, USA). The manufacturer’s 
SNP-FASST2 segmentation algorithm was used to make 
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copy number and loss of  heterozygosity estimations. Whole 
chromosomes were counted as gained or lost when at 
least 90% of  the probe signals from both chromosome 
arms were above or below the defined threshold as described 
previously (14). For acrocentric chromosomes (13–15, 21, 
22) only q-arm changes were counted as whole chromo-
somal gains or losses. We applied GISTIC (Genomic 
Identification of  Significant Targets in Cancer) to distin-
guish significant chromosomal aberrations from random 
background (3).
Targeted Sequencing
Targeted next generation sequencing was performed at Mayo 
Clinic using the clinically validated Neuro-Oncology 
Expanded DNA Panel (https://www.mayoc linic labs.com/test-
catal og/Overv iew/603047). The DNA subpanel assesses for 
alterations in 150 genes associated with CNS tumors and 
utilizes a QIAseq Targeted DNA custom amplicon-based 
panel with molecular bar code technology to allow traceability 
of PCR artifacts/duplicates. Sequencing was performed using 
an Illumina HiSeq 2500 (Illumina, Inc., San Diego, CA; 
paired-end, 2  ×  151). The RNA subpanel was performed 
in a subset of cases lacking BRAF p.V600E or other MAPK 
alteration. The RNA panel utilizes a QIAseq Targeted 
RNAscan custom amplicon-based panel designed to detect 
104 known gene-gene fusions and novel fusion transcripts, 
including BRAF-KIAA1549 fusion. Paired-end 231/71 
sequencing was performed on an Illumina MiSeq instrument. 
A gene list is included in the supplementary methods. DNA 
and RNA panel data were processed through custom bio-
informatics pipelines developed to detect single nucleotide 
variants and small insertions/deletions (< 50 base pairs) 
with at least 15% variant allelic frequency and gene fusion 
events with at least 10 fusion transcripts, respectively. Variants 
with  <  15 supporting molecules were excluded. DNA and 
RNA sequence alterations were visualized using Alamut 
Visual (Interactive Biosoftware, Rouen, France) and integra-
tive genome browser (IGV) (34), respectively. DNA sequence 
alterations classified as benign based on publicly available 
data from genetic databases and literature were excluded.
TERT promoter mutation analysis
Targeted analysis of the TERT promoter was performed 
by pyrosequencing or digital droplet PCR (ddPCR). 
Prosequencing analysis of the TERT promotor hotspots 
(C228 and C250) was performed as previously described 
(11). ddPCR was performed using two TaqMan assays for 
specific for TERT C228T and C250T (Biorad, Hercules CA). 
PCR products were analyzed on a QX200 droplet reader 
(Biorad) and analyzed with QuantaSoft software (Biorad). 
Further details are available in supplementary methods.
Genome-wide methylation profiling
Genome-wide methylation profiling was performed in 35 
patients from the Mayo Clinic/JHH Hopkins and 23 patients 
from the German cohort using Illumina Infinium Human 
MethylationEPIC BeadChip (850K). The methylation data 
were preprocessed using the minfi package (v.1.28.4) (2) 
in R (http://www.r-proje ct.org, version 3.5.3). Quality con-
trol was performed by examining the detection P-value 
and calculating the median log (base2) intensities for 
methylated and unmethylated signals for each array. Samples 
with  detection P-value less than 0.01 and unmethylated 
and methylated median  intensity values above 10 were 
carried forward for subsequent analysis. Beta density plots 
for all samples before and after normalization were also 
examined. After the quality control process, 46 samples 
were carried forward in the subsequent methylation 
analysis.
Functional normalization (8) with NOOB background 
correction and dye-bias normalization (35) was performed. 
Probe filtering was performed after normalization. 
Specifically, probes located on sex chromosomes, contain-
ing nucleotide polymorphism (dbSNP132 Common) within 
five base pairs of  and including the targeted CpG-site or 
mapping to multiple sites on hg19 (allowing for one mis-
match), as well as cross reactive probes were removed 
from analysis.
Unsupervised analysis of methylation data was performed 
using t-distributed stochastic neighbor embedding (t-SNE) 
using Rtsne (v.0.15) in comparison to the published Heidelberg 
reference cohort (6). In brief, principal components were 
calculated using the 5000 most variably methylated CpG 
probes, as measured by the standard deviation (SD) of the 
probe-level beta values across samples. The top 13 principal 
components which explained more than 99% of the total 
variance across all samples were used as input in the t-SNE 
analysis.
Mate-pair sequencing
Mate-pair sequencing is a whole-genome protocol that detects 
structural and copy number variation. DNA extraction and 
mate pair library preparation were performed as previous 
described (26). Briefly, DNA was isolated using the Qiagen 
Puregene extraction kit and processed using the Illumina 
Nextera Mate Pair library preparation kit and sequenced 
on the Illumina HiSeq 4000. DNA was fragmented at 2-5 kb 
fragments and sequenced from both ends. The sequencing 
data were mapped to the reference genome (GRCh38) using 
BIMA and the output was analyzed using SVAtools 
(7, 18). Junctions and CNAs were graphically illustrated 
using genome and junction plots as previously described 
(10).
Statistical analyses
Patient and clinicopathologic characteristics were summa-
rized with frequencies and percentages or medians and 
ranges, as appropriate. Comparisons between groups (i.e., 
PXA II vs. A-PXA) were performed with Fisher’s exact 
(categorical data) or Wilcoxon rank-sum tests (ordinal 
data). Progression was defined as the first recurrence or 
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death caused by disease (whichever occurred earlier). 
Progression-free survival (PFS) and overall survival (OS) 
were summarized using the Kaplan-Meier method (5-year 
survival) and were compared between groups with likeli-
hood ratio tests from Cox proportional hazards regression 
models. Survival estimates and hazard ratios were reported 
along with 95% confidence intervals (CI). P-values less 
than 0.05 were considered statistically significant. All 
analyses were performed using SAS version 9.4 (SAS 
Institute Inc., Cary, NC) or R.
RESULTS
Patient cohort characteristics
Characteristics of the overall cohort of 67 patients diagnosed 
with PXA or A-PXA are shown in Figure  1 and detailed 
in Supporting Table  S1. Median age at initial diagnosis was 
20.3 years (range: 5.6 to 73.1 years), with 28 tumors (41.8%) 
occurring in pediatric patients (<18  years of age) and 39 
(58.2%) in adults (Figure  S1). The vast majority of tumors 
occurred in a supratentorial location (n  =  64), most fre-
quently the temporal lobe (n  =  32), with rare (n  =  3) 
posterior fossa tumors. A similar proportion of patients 
were female (n  =  37, 55.2%) and male (n  =  30, 44.8%). 
At primary diagnosis, the majority of patient were diagnosed 
with PXA grade II (n  =  53, 79.1%) vs. A-PXA (n  =  14, 
20.9%). There were no significant differences in age or gender 
between patients diagnosed with PXA vs. A-PXA (Table S1). 
Patients from the German cohort were younger relative to 
the Mayo/JHH cohort (median age: 15.4 years vs. 21.9 years) 
and more frequently diagnosed as PXA grade II (96.9% 
vs. 62.9%) (Table S1). Overall, our cohort reflects the typical 
demographics of PXA patients (13).
Genomic analysis
In 65 cases, genomic analyses were performed on specimens 
obtained at initial resection, while 2 cases had tissue avail-
able only at first recurrence, including one tumor that 
had undergone anaplastic transformation. Tumors were 
assessed for the BRAF p.V600E mutation by targeted 
sequencing (n  =  59) or IHC alone (n  =  8) (Figure  1). 
Overall, 51 tumors (76.1%) were positive for BRAF p.V600E, 
including PXA (79.2%) and A-PXA (64.3%) (Table  S2). 
All tumors were analyzed for genome-wide copy number 
by molecular inversion probe (MIP) technology (Figure S2). 
The most frequent alteration was loss of  CDKN2A/B, 
present in the vast majority of  cases (n  =  63; 94%). In 
53 cases, CDKN2A/B showed homozygous deletion. Ten 
cases showed at least hemizygous loss of  CDKN2A/B, but 
Figure 1. Clinical and molecular characteristics of the patient cohort. 
BRAF p.V600E mutations were identified by targeted sequencing or (●) 
immunohistochemistry (IHC) only. TERT promoter mutations were 
identified by targeted sequencing or ddPCR. CDKN2A/B deletion and 
whole chromosome gains and losses were derived from MIP data. 
Genome-wide methylation data were analyzed against the Heidelberg 
reference brain tumor cohort (6). Methylation class was defined by 
unsupervised analysis using t-SNE dimensionality reduction and utilizing 
the Heidelberg online classification tool (classifier version v11b4). A 
calibrated Heidelberg score of >0.9 (●) was considered a definitive 
match to the reference methylation class. ANA PA, anaplastic pilocytic 
astrocytoma; LGG-GG, low-grade glioma, ganglioglioma; LGG-PA/GG-
ST, low-grade glioma, subclass hemispheric pilocytic astrocytoma and 
ganglioglioma; CONT INFLAM, control tissue, inflammatory tumor 
microenvironment; CONT REACT, control tissue, reactive tumor 
microenvironment; GBM RTK II, glioblastoma, IDH wild-type, subclass 
RTK II; GBM G34, glioblastoma, IDH wild-type, H3.3 G34 mutant; PLEX 
PED B, plexus tumor, subclass pediatric B; GBM MES, glioblastoma, 
IDH wild-type, subclass mesenchymal; NA, not available; LTF, lost to 
follow-up. [Colour figure can be viewed at wileyonlinelibrary.com]
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in a subset of  six cases, the deletion could not be une-
quivocally interpreted as hemizygous vs. homozygous loss 
because of  DNA quality, small deletion size or tumor 
cellularity. To further evaluate this finding, IHC for p16 
was performed in 33 cases. In cases with CDKN2A/B 
homozygous deletion, a complete loss of  p16 protein 
expression was observed in 22 (of  23) cases while 1 case 
showed protein loss only in a subset of  cells. In 6 (of 
6) tumors with hemizygous or questionable hemi/homozy-
gous deletion, p16 expression was also lost. Expression 
was retained in 3 (of  4) tumors lacking CDKN2A/B 
deletion.
By genome-wide chromosomal copy number analysis 
(MIP), most cases also demonstrated additional chromo-
somal gains/losses, predominantly involving whole chro-
mosomes or chromosomal arms (Figure  S2). The most 
frequent whole chromosome gains were gain +7 (n  =  17), 
+5 (n  =  12), +12 (n  =  10), +21 (n  =  10), +2 (n  =  10) 
and +20 (n  =  9). The most frequent losses were loss −9 
(n  =  24), −22 (n  =  9) and −13 (n  =  8). Tumors tended 
to show a predominance of  either chromosomal gains or 
losses, but this pattern was not associated with tumor 
grade or other molecular features. Loss −10 was less com-
mon (n  =  6) and no tumors demonstrated concurrent 
gain +7/loss −10, characteristically found in glioblastoma 
(5). No focal amplifications (including TERT) were identi-
fied. A-PXA showed a significantly higher number of  whole 
chromosome CNAs than PXA grade II (median 5.5 vs. 
1.0; P  =  0.004). Gain +7, +20 and +21 were more fre-
quent in A-PXA (Table  S2).
To further characterize the pattern of CNAs, mate-pair 
sequencing was performed in 6 cases with available frozen 
tumor tissue (3 PXA and 3 A-PXA) (Figure  S3). In 5 
cases, CDKN2A/B deletion resulted from a small interstitial 
deletion, while case 51 showed a more complex intrachro-
mosomal rearrangement of 9p. Genome-wide, chromosomal 
translocations were not identified in two cases while three 
cases showed a small number of translocations that did 
not result in relevant gene fusions. In contrast, case 45 
demonstrated a complex pattern consistent with chromoth-
ripsis and chromoplexis (Figure  S4). This involved multiple 
chromosomes, with an intrachromosomal event of 3p result-
ing in ATG7-RAF1 fusion, an alteration previously reported 
in an A-PXA (28).
In 31 cases (21 PXA; 10 A-PXA), DNA was available 
in suitable quality to perform targeted next generation 
sequencing of 150 CNS tumor associated genes. In an addi-
tional 32 cases, targeted sequence analysis of the TERT 
promoter was performed by pyrosequencing or digital droplet 
PCR (ddPCR). In most PXA grade II cases, BRAF p.V600E 
was the sole pathogenic alteration identified by NGS 
(Figure  1). Of the BRAF p.V600 wild-type PXAs, two cases 
harbored previously reported BRAF activating insertion/
deletion mutations: BRAF p.V504_R506dup and BRAF 
p.L485_P490delinsF, the latter identified in conjunction with 
a splice site mutation in NF1 (29). ATG7-RAF1 fusion was 
present in two cases, including case 45 characterized by 
mate-pair sequencing. Thus, alternative MAPK pathway 
alterations were identified in all PXA analyzed by targeted 
NGS. A single PXA harbored a TERT promoter mutation 
and another single tumor an inactivating mutation in 
PIK3C2G. Alterations in ATRX, TP53 or PTEN were not 
identified in PXA grade II.
Of  10 A-PXA analyzed by targeted NGS testing, 7 
harbored a BRAF p.V600E mutation. Additional mutations 
were identified in 5 (of  7) BRAF-mutant A-PXA, involv-
ing TERT (n  =  1), ATRX (n  =  2), TP53 (n  =  1) and 
PIK3C2G (n  =  1). The TP53 mutation (c.783-2A  >  G) 
involved the splice acceptor site and has been previously 
reported. Overall, targeted TERT promoter analysis identi-
fied mutations in 2 of  14 (14.3%) A-PXA. Three A-PXA 
harbored an unusual molecular profile, characterized by 
NF1 mutation in a background of  marked chromosomal 
aneuploidy (Figure  S5). Case 62 showed an NF1 p.L844F 
mutation, a point mutation in PTEN and an apparently 
triploid genome, with complex superimposed CNAs. Cases 
63 and 64 harbored truncating mutations in NF1 and 
showed an almost identical CNA profile, characterized by 
a near haploid genome. Review of  tumor histology con-
firmed the diagnosis of  A-PXA in these cases (Figure  S5). 
Case 62 showed predominance of  large, pleomorphic, 
lipidized cells and prominent perivascular inflammation. 
Cases 63 and 64 showed more classic morphology, with 
necrosis (both cases) and microvascular proliferation 
(case 64).
In nine cases, BRAF p.V600 was wild-type, but tissue 
could not be further analyzed by NGS. As a surrogate for 
MAPK pathway activation, phospho-ERK immune staining 
was performed in 5 BRAF p.V600 negative cases and in 
10 cases with known MAPK alterations. pERK was positive 
in all tumors examined, supporting MAPK pathway activa-
tion as a hallmark of PXA.
Methylation-based classification
Tumor classification of  46 cases (31 PXA; 15 A-PXA) 
was performed based on genome-wide methylation data 
obtained from the Illumina MethylationEPIC array. Two 
tumors analyzed at recurrence/anaplastic progression only 
are included with A-PXA. These tumors were classified 
against a comprehensive reference data set (6) by two 
independent methods: an unsupervised t-SNE (t-distributed 
stochastic neighbor embedding) analysis and the Heidelberg 
supervised brain tumor classifier, version v11b4 (6) (https://
www.molec ularn europ athol ogy.org/mnp). t-SNE analysis 
was performed using a subset of  14 reference classes 
(Figure  2A); inclusion of  all reference classes did not 
substantially alter classification (not shown). Among 46 
cases, both methods consistently classified 38 cases with 
the PXA (n  =  36), hemispheric pilocytic astrocytoma and 
ganglioglioma (n  =  1) and ganglioglioma (n  =  1) refer-
ence methylation classes.
By unsupervised t-SNE, most cases grouped with PXA 
(n  =  40) and the remaining with the classes anaplastic pilo-
cytic astrocytoma (n = 2), hemispheric pilocytic astrocytoma 
and ganglioglioma (n = 1), ganglioglioma (n = 1) or control 
tissues (n  =  2). The anaplastic pilocytic astrocytoma refer-
ence group utilized in this analysis contains 21 tumors (6), 
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which subsequently all clustered with the newly defined entity 
anaplastic astrocytoma with piloid features (30) (D. Capper, 
personal communication). Of the tumors grouping with PXA, 
there was no apparent subgrouping related to WHO grade, 
genomic driver alterations or CDKN2A/B deletion status 
(Figure  2B-D). Analysis using the Heidelberg methylation 
brain tumor classifier (v11b4) available as an online tool 
yielded a definitive assignment to a reference class (defined 
by a calibrated score ≥ 0.9) for 26 tumors (56.5%) (Table S3). 
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PXA grade II (n  =  20, 64.5%) than for A-PXA (n  =  6, 
40.0%). Overall, for 38 tumors (82.6%), PXA was the high-
est scoring reference class, including 24 (52.2%) with 
scores  ≥  0.9. Only two tumors showed a high score for 
other low-grade glioma reference classes, consistent with the 
t-SNE analysis (Figure  1). Overall, in the majority of cases, 
methylation profiling was concordant with the histologic 
diagnosis of PXA.
For cases with discordant classification by methylation 
profiling, tumor histology was re-reviewed (Figure  S6). All 
were considered to remain in keeping with PXA. Neither 
of the two cases matching to other low-grade glioma meth-
ylation classes (case 1 and 2) demonstrated a definitive 
ganglion cell component and were more cellular and pleo-
morphic than typical of pilocytic astrocytoma. The two 
cases grouping with anaplastic pilocytic astrocytoma (case 
23 and 41) were both cerebellar PXA grade II, with char-
acteristic morphology. The two cases matching to the “control 
tissue” methylation classes (cases 4 and 62) both showed 
solid tumor histologically. Although an inflammatory com-
ponent was apparent in case 62, the CNA profile supported 
high tumor cell content (Figure  S5B).
Genomic characterization of matched primary 
and recurrent samples
In 9 cases, genomic analyses were performed on matched 
primary and recurrent tumors, including 2 cases at both 
first and second recurrences (Figure  3). Case 38 received 
radiotherapy prior repeat resection; the remaining cases did 
not receive radiation or chemotherapy prior to recurrence. 
Tumors underwent anaplastic transformation on recurrence 
in 8 cases while one patient presented initially with an 
A-PXA. Recurrent tumors were analyzed by MIP genome-
wide copy number analysis (n = 9), TERT promoter analysis 
(n  =  9) and methylation profiling (n  =  6). The majority 
of tumors showed an increase in complexity at recurrence, 
with acquisition of multiple additional CNAs (Figure  3A). 
The changes were largely non-recurrent, although gains of 
chromosomes 2 (n  =  2) and 7 (n  =  2) as well as loss of 
chromosome 10 (n  =  2) were identified in multiple tumors 
at recurrence. In two cases, TERT promoter mutations were 
acquired at recurrence (case 22 and 38). For the 6 matched 
samples analyzed by methylation profiling, the methylation 
class was stable for tumors grouping with the PXA (n  =  5) 
and anaplastic pilocytic astrocytoma methylation class 
(n  =  1) (Figure  3C).
In two cases, tissue was available from matched low- and 
high-grade components within the same tumor. Additional 
CNAs were present in the high-grade component of both 
tumors, including loss of chromosome 6 (Figure  3B). 
Additionally, TERT mutation was identified only in the 
high-grade component of case 53. Methylation class was 
preserved between the low- and high grade components of 
case 67 (Figure  S7). Overall, our results suggest that on 
recurrence or anaplastic transformation, the methylation class 
is preserved. The majority of tumors acquire additional, 
largely non-recurrent CNAs and a subset acquires TERT 
promoter mutations.
Association of histology and genomic features 
with patient outcome
Follow-up was available for 62 patients, with a median follow-
up period of 5.4  years (Table  S4). Overall, histologic WHO 
grade was a strong predictor of patient overall survival 
(P < 0.001). A trend toward decreased progression-free survival 
was also present, but this did not reach statistical significance 
(P = 0.05) (Figure 4A,B). For PXA, five-year progression-free 
survival was 59.9% (95% CI: 45.0%, 74.8%) and overall sur-
vival was 80.8% (95% CI: 68.8%, 92.9%). For A-PXA, five-
year progression-free survival was 39.3% (95% CI: 12.7%, 
65.9%) and overall survival 47.6% (95% CI: 20.1%, 75.1%). 
Limiting survival analysis to the 38 cases that were confi-
dentially assigned to the PXA methylation class by methylation-
based classification showed consistent results (Figure  4C,D); 
the presence of anaplastic features remained strongly associated 
with overall survival (P  =  0.002) with a non-significant trend 
toward decreased progression-free survival (P = 0.09) in those 
PXA defined by methylation-based classification.
The presence of necrosis was also strongly associated shorter 
overall survival (P  =  0.0003, Table  S4). Five-year overall 
survival was 86.3% for tumors with no necrosis (95% CI: 
74.9, 97.9) vs. 43.8% for tumors with necrosis (95% CI: 20.5, 
67.0). However, given a strong association of necrosis with 
elevated mitotic activity and relatively small number of cases, 
we were unable to reliably evaluate necrosis and mitotic index 
as independent predictors of survival. Associations between 
patient survival and molecular genetic features were less 
robust. Neither the total number of whole chromosome CNAs 
nor any individual whole chromosome gain or loss showed 
a significant association with overall survival (Table  S4). 
CDKN2A/B deletion was not associated with overall survival 
(P  =  0.18), although the power of this analysis was very 
Figure 2. Genome-wide methylation profiling and methylation-based 
classification of PXA. (A) Clustering of PXA relative to published 
reference methylation classes. Analysis was performed using the top 
5000 most differentially methylated probes with t-SNE visualization. 
Current series denotes cases from our cohort. (B-D) Grouping of current 
cases relative to (B) tumor grade, (C) genetic driver alteration and (D) 
CDKN2A/B deletion type. Reference cases are shown in grey within the 
area denoted in red in panel A. Reference methylation classes included: 
PXA, (anaplastic) pleomorphic xanthoastrocytoma; ANA PA, anaplastic 
pilocytic astrocytoma; LGG-GG, low-grade glioma, ganglioglioma; LGG-
PA/GG-ST, low-grade glioma, subclass hemispheric pilocytic astrocytoma 
and ganglioglioma; CONT-INFLAM, control tissue, inflammatory tumor 
microenvironment; CONT-HEMI, control tissue, hemispheric cortex; 
CONT-REACT, control tissue, reactive tumor microenvironment; 
glioblastoma IDH wild-type subgroups: GBM-MES, mesenchymal 
subclass; GBM-MID, midline subclass; GBM-RTK-I subclass; GBM RTK-
II subclass; GBM-RTK-III subclass; pedRTK I subclass; GBM-MYCN 
subclass. Two cases analyzed at only recurrence/anaplastic 
transformation are included with A-PXA. [Colour figure can be viewed at 
wileyonlinelibrary.com]
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limited as only three cases in our series lacked CDKN2A/B 
deletion and had clinical follow-up available. TERT promoter 
mutations were rare (n  =  3), but showed strong association 
with shorter overall survival (P  =  0.002), with no patients 
alive at five years. An insufficient number of cases harbored 
other molecular alterations, including ATRX, TP53 and NF1 
mutations, to correlate with patient survival.
DISCUSSION
This cohort of PXA patients is unique for the number of 
cases and the detailed correlation of clinical, histologic and 
genomic features with long-term clinical follow-up. The study 
confirms that the vast majority of PXA are characterized 
genetically by the presence of CDKN2A/B deletion in com-
bination with MAPK pathway alterations (Figure  1). While 
BRAF p.V600E was the most frequent driver alteration 
(n  =  51, 76.1%), we also identified previously reported 
alterations of BRAF (29) and RAF1 (28). Three A-PXA 
showed an unusual genomic profile, characterized by NF1 
mutation and marked aneuploidy (Figure S5), including two 
confirmed by methylation-based classification. NF1 has been 
described as a somatic mutation in PXA (4) and PXA 
rarely occur in the setting of neurofibromatosis type 1, the 
Figure 3. Genomic analysis of matched primary and recurrent tumors. 
(A) Genomic characterization of 9 matched primary and recurrent 
tumors. In 8 cases, tumors underwent anaplastic transformation upon 
recurrence. (B) Analysis of distinct areas of low-grade and high-grade 
morphology in A-PXA. DNA was extracted and analyzed independently 
from histologically low-grade and high-grade areas within the same 
tumor. Tumors were analyzed by chromosomal microarray and targeted 
sequencing of BRAF and TERT. (C and D) Genome-wide methylation 
profiling of matched primary and recurrent tumors. Matched tumors 
were analyzed in comparison to the 14 reference methylation classes 
included in Figure  2. (D) Details of tumor pairs within the PXA and 
anaplastic pilocytic astrocytoma (ANA PA) methylation class. NA, not 




Vaubel et alBiology and Grading of PXA
Brain Pathology 31 (2021) 20–32
© 2020 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology
28
majority low-grade (37). However, to our knowledge, this 
molecular profile has not been previously reported in A-PXA.
Multiple studies have identified CDKN2A/B deletion to 
be a frequent genomic alteration in PXA (20, 27, 36, 39). 
However, the frequency at which it has been observed has 
varied across studies, from approximately 60% (20, 39) up 
to 100% (27). While this may in part reflect variability across 
patient cohorts, it is also likely to result from technical 
differences in the methods used to detect CDKN2A/B dele-
tion. In our series, CDKN2A/B loss was present in 63 cases 
(94%), although in 10 cases the loss was hemizygous or 
could not be unequivocally interpreted as hemi- vs. homozy-
gous deletion. This variability in detection sensitivity has 
important implications as CDKN2A/B becomes increasingly 
utilized as a diagnostic and prognostic marker. The MIP 
technology used in this study represents a high-resolution, 
quantitative method for the assessment of allele-specific copy 
numbers in FFPE archival tissue. As CDKN2A/B deletion 
was present in the vast majority of our cases, we are unable 
to assess its prognostic significance in PXA. Only three 
tumors in our series lacked CDKN2A/B deletion and had 
clinical follow-up available, although none of these tumors 
recurred. In other tumor types, including pediatric gliomas 
(21) and IDH-mutant astrocytomas (33) CDKN2A/B dele-
tion is an adverse prognostic factor. However, in PXA, it 
appears to be a defining molecular alteration likely repre-
senting an early pathogenic event, present in both low-grade 
and anaplastic PXA.
In comparison to PXA grade II, A-PXA showed a 
higher number of  whole chromosome CNAs (Table  S2) 
Figure 4. Patient survival relative to histologic grade. Kaplan-Meir curves showing (A) progression-free survival and (B) and overall survival across all 
cases with available follow-up. (C) Progression-free survival and (D) overall survival limited to 38 tumors grouping with PXA by methylation profiling. 
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and a subset harbored additional pathogenic alterations, 
including mutations of  TERT, ATRX and TP53 (Figure 1). 
These findings are comparable to a recently published 
genetic characterization of  15 A-PXA from UCSF (27). 
However, this series reported a high frequency of  TERT 
alterations, identified in 47% (7 of  15) of  A-PXA (27). 
Two of  these tumors harbored TERT amplification rather 
than promoter mutation, an alteration we did not observe. 
In our cohort, TERT promoter mutations were uncom-
mon, identified in 2.0% of  PXA grade II and 14.3% of 
A-PXA. A difference between the UCSF series and our 
series is that the majority of  the A-PXA in the UCSF 
series (9 of  15, 60%) were analyzed at recurrence (27) 
and TERT alterations were more frequent in recurrent 
tumors (5 of  9; 56%). No details were provided regarding 
adjuvant treatments patients received prior to recurrence. 
Additionally, 2 (of  9) tumors in our series (Figure  3) and 
1 (of  4) tumors in the UCSF series acquired TERT muta-
tion at recurrence, suggesting that TERT promoter muta-
tions may be a late event associated with recurrence and 
anaplastic transformation. A high frequency of  TERT 
alterations was also identified in a group of  PXA utilized 
as a reference in comparison to epithelioid glioblastoma 
(20). In this cohort, TERT promoter mutations were 
observed in 19% of  PXA grade II and 36% of  A-PXA. 
The clinicopathologic features of  this cohort have not 
been independently reported. Overall, our findings suggest 
that additional CNAs and pathogenic mutations are present 
in A-PXA, including TERT promoter mutations. However, 
no single recurrent alteration seems to underlie anaplastic 
transformation.
For the majority of  cases in our series, methylation-
based classification was concordant with the histologic 
diagnosis of  PXA (Figure  2, Table  S3). In only two cases 
both unsupervised t-SNE clustering and supervised analysis 
using the Heidelberg classifier unequivocally reassigned 
tumors to other entities. Both were PXA grade II by 
histology, which matched to other low-grade glioma meth-
ylation groups (pilocytic astrocytoma or ganglioglioma). 
Intriguingly, these were the only two cases submitted for 
methylation profiling that lacked CDKN2A/B deletion. By 
unsupervised clustering, an additional two PXA cases 
grouped with the methylation class of  anaplastic pilocytic 
astrocytoma (Figure  2). The cases included in this refer-
ence group cluster with the subsequently described ana-
plastic astrocytoma with piloid features (30). Notably, these 
were the only two cerebellar tumors analyzed, suggesting 
a possible influence of  tumor site on the methylation 
profile. While methylation profiling was largely concordant 
with histology, the Heidelberg classifier did not uniformly 
provide a definitive diagnosis, with low-confidence calls 
(calibrated score  <  0.9) in 34.4% of  cases overall and 
60.0% of  A-PXA (Table  S3). This is in keeping with a 
recently published series, in which 44% of  pediatric low-
grade gliomas similarly showed low-confidence calls using 
this tool (9). Across our series, methylation profiling largely 
confirmed the diagnosis of  PXA and did not provide 
additional information likely to alter clinical management. 
In fact, its inability to distinguish low- and high-grade 
PXA represents a significant limitation of  methylation-
based classification in this setting.
Within this cohort, WHO grade was the most significant 
prognostic factor. The presence of anaplastic features (defined 
by  >  5 mitoses per 10 high-power fields (area of 0.23 mm2) 
was a strong predictor of patient overall survival (P < 0.001) 
with a trend toward decreased progression-free survival 
(P = 0.05) (Figure 4). This was consistent even when limited 
to those 38 tumors that could be defined as PXA both by 
histology and methylation-based classification (Figure 4C,D). 
These findings parallel those of a recent study showing the 
importance of histology in determining prognosis of pediatric 
gliomas with a PXA-like methylation signature (9). Although 
identified in a small number of cases, our findings also 
suggest that TERT mutation may be associated with poor 
patient outcome. Each of the three patients with TERT-
mutant tumors at initial resection died, including one patient 
with a PXA grade II (Figure  1). In keeping with this, the 
UCSF case series, which identified TERT promoter muta-
tions in 47% of A-PXA, reported an extremely high rate 
of recurrence (12 of 13 patients) with very short recurrence-
free survival (median 1.3  years) (27). In contrast, in our 
series, 5-year recurrence free survival for A-PXA was 40.9%. 
Larger series with long-term follow-up are needed to clarify 
the role of TERT promoter mutation in PXA.
Our study was restricted to PXA with well-defined his-
tologic features. As such, methylation-based classification 
was largely confirmatory. A number of recent studies have 
reported tumors that can be assigned to the PXA methyla-
tion class but lack its characteristic morphology, including 
epithelioid glioblastoma (20), astroblastoma (22) and a subset 
of pediatric gliomas (23). While the relationship of these 
tumors to PXA remains incompletely understood, our results 
emphasize the importance of careful histologic examination 
and correlation with long-term follow-up. While “PXA-like” 
tumors may have more favorable outcomes than IDH-wild-
type glioblastoma, it is premature to assume that all will 
have outcomes analogous to PXA.
In summary, our results confirm that the vast majority 
of PXA harbor CDKN2A/B deletion in conjunction with 
alterations of the MAPK pathway. In both histologically 
and epigenetically defined PXA, tumor WHO grade remains 
a strong predictor of patient survival. Methylation profiling 
may be useful in tumors with ambiguous morphology, but 
serves largely to confirm the diagnosis in cases with classic 
histology.
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version of this article at the publisher’s web site:
Figure S1. Age and gender distribution of PXA patients. Age 
at first diagnosis is shown for 67 patients. M, Male; F, Female.
Figure S2. Copy number alterations in PXA. (A) Genome-
wide copy number alterations. (B) Copy number alterations of 
9p, highlighting homozygous deletions of CDKN2A/B. Case 
order matches that of Figure 1. cnLOH, copy neutral loss of 
heterozygosity.
Figure S3. Structural rearrangements determined by mate-pair 
sequencing. Genome U-plots are shown with chromosomes 
plotted in order of size as denoted on the y-axes. Copy num-
ber gains are shown in blue and losses in red. Structural rear-
rangements are depicted as connecting lines, with unbalanced 
translocations in magenta, balanced translations in dark green, 
transposons in light green, and complex or ambiguous rear-
rangements in orange. For unbalanced translocations, red or 
blue ends denote reads mapped to reverse or forward strand, 
respectively.
Figure S4. Structural rearrangements of case 45. (A) Genome 
plot of case 45. Complex structural rearrangements were 
identified, including chromoplexis involving chromosomes 6, 
13, 16, and 22. (B) Junction plot demonstrating ATG7-RAF1 
fusion. The fusion involved intronic regions resulting in fusion 
of ATG7 exons 1-18 with RAF1 exons 11-17.
Figure S5. Histology and copy number profiles of NF1-mutant 
A-PXA. (A) Morphology of NF1-mutant A-PXA. Case 62 
showed a predominance of large, pleomorphic and variably 
lipidized cells, with prominent perivascular inflammation. 
Cases 63 and 64 showed prominent spindled morphology, 
admixed with pleomorphic and scattered xanthomatous cells. 
All cases demonstrated > 5 mitoses per 10 high-power fields. 
Case 63 also showed necrosis and case 42 both necrosis and 
microvascular proliferation. H&E photomicrographs shown at 
200x (top panel; scale bar = 100 μM) and 400x (bottom, scale 
bar = 50 μM) magnification. (B) Genome-wide copy number 
profiles of NF1-mutant A-PXA. Case 62 showed an appar-
ently triploid genome with many additional complex CNVs. 
Cases 63 and 64 showed a nearly identical pattern of CNVs, 
with a near haploid genotype and homozygous deletion of 
CDKN2A/B.
Figure S6. Histology of PXA clustering with other reference 
groups. Cases 1 and 2 demonstrated pleomorphic, low-grade 
gliomas. No apparent ganglion cell component was identified 
by immunohistochemistry (not shown). Case 2 showed numer-
ous eosinophilic granular bodies and was more cellular than 
typical of pilocytic astrocytoma. Cases 4 and 62 showed cellu-
lar tumor consistent with PXA. Cases 41 and 23 were cerebel-
lar tumors with spindled and pleomorphic components. Case 
40 is shown at initial resection and at recurrence. The recur-
rent tumor was high-grade and unrecognizable as a PXA, with 
small cell morphology, necrosis, and microvascular prolifera-
tion. H&E photomicrographs shown at 200x (left panel) and 
400x (right panel) for each case.
Figure S7. t-SNE of distinct low- and high-grade areas of case 
67. Histologically low-grade (grey) and high-grade (black) 
components from case 67 were analyzed independently by 
methylation profiling. Reference methylation classes included: 
PXA, (anaplastic) pleomorphic xanthoastrocytoma; ANA PA, 
anaplastic pilocytic astrocytoma; LGG-GG, low-grade gli-
oma, ganglioglioma; LGG-PA/GG-ST, low-grade glioma, sub-
class hemispheric pilocytic astrocytoma and ganglioglioma; 
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CONT-INFLAM, control tissue, inflammatory tumor micro-
environment; CONT-HEMI, control tissue hemispheric 
cortex; CONT-REACT, control tissue, reactive tumor micro-
environment; glioblastoma IDH wildtype subgroups: GBM-
MES, mesenchymal subclass; GBM-MID, midline subclass; 
GBM-RTK-I subclass; GBM RTK-II subclass; GBM-RTK-
III subclass; pedRTK I subclass; GBM-MYCN subclass.
Table S1-S4
Table S1. Characteristics of patient cohort.
Table S2. Association of genomic alterations with tumor grade.
Table S3. Tumor classification by genome-wide methylation 
profiling.
Table S4. Association of clinical, histologic, and genomic 
characteristics with patient overall survival.
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